z-logo
Premium
A Visible‐ and NIR‐Light Responsive Photothermal Therapy Agent by Chirality‐Dependent MoO 3− x Nanoparticles
Author(s) -
Li Yiwen,
Miao Ziwei,
Shang Zhengwen,
Cai Ying,
Cheng Jiaji,
Xu Xiaoqian
Publication year - 2020
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.201906311
Subject(s) - chirality (physics) , photothermal therapy , materials science , nanoparticle , visible spectrum , circular polarization , supramolecular chirality , photothermal effect , nanotechnology , nanomaterials , photochemistry , molecule , optoelectronics , optics , supramolecular chemistry , chemistry , organic chemistry , physics , chiral symmetry breaking , quantum mechanics , nambu–jona lasinio model , quark , microstrip
Chirality‐based semiconducting nanocrystals, as an emerging area, are envisioned to have great potential in chiral sensing, biomedicine, and chiroptical devices. Herein, chiral substoichiometric molybdenum oxide ( l / d ‐Cys‐MoO 3− x ) nanoparticles are synthesized via step‐by‐step reduction treatment with chiral cysteine molecules. The obtained nanoparticles are used as visible‐ and near‐infrared‐light dual responsive photothermal therapy agent for tumor cell ablation. Notably, the chiral nanoparticles show chiral selectivity for incident light, i.e., when irradiated by left‐circularly polarized light, l ‐Cys‐MoO 3− x is the most sensitive agent giving the highest mortality for HeLa cell ablation in vitro, and vice versa for right‐circularly polarized light with d ‐Cys‐MoO 3− x . In comparison to traditional photothermal therapy with near‐field light source, the investigations with chiral visible light at 532 nm indicate the possibility of chiral Cys‐MoO 3− x nanoparticles for visible light‐based phototherapy via metal–ligand charge transfer chirality, which provides insights for new methods in nanotechnology supported photothermal treatments.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here